Human CLDN18-A2 Virus-Like Particles

Human Claudin 18.2 (CLDN18-A2) Virus-Like Particles (VLPs) represent a sophisticated tool for presenting the complex, four-pass transmembrane protein CLDN18.2 in its authentic conformational state. CLDN18.2 is a highly selective splice variant primarily expressed in the tight junctions of gastric mucosa and is significantly upregulated in various gastrointestinal malignancies. These VLPs are engineered to self-assemble into non-infectious, shell-like particles that incorporate the target protein directly into a lipid bilayer. This method bypasses the limitations associated with traditional recombinant protein production, such as the need for harsh detergents that can disrupt the protein’s natural folding. By maintaining the native structure of the extracellular loops, these VLPs provide a high-quality antigen that accurately reflects the surface topology of cancer cells.

The utility of Human CLDN18-A2 VLPs extends across several critical stages of biopharmaceutical development. They are predominantly used as immunogens for antibody generation and as capture targets in high-throughput screening assays, including phage display and B-cell sorting. Their ability to simulate a cell-membrane environment makes them exceptionally effective for validating the binding specificity of monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs) through techniques like ELISA and Flow Cytometry (FACS). Furthermore, these VLPs serve as indispensable tools for characterizing the potency of CAR-T cell therapies, allowing researchers to assess receptor-ligand interactions in a controlled, cell-free system. By providing a reliable and stable source of the CLDN18.2 antigen, these particles accelerate the development of precision medicines targeting difficult-to-treat solid tumors.